Vernalis plc today announces that CTI BioPharma Corp. (CTI), a US corporation publicly listed on NASDAQ, replaces the UK venture capital backed Chroma Therapeutics (Chroma) as worldwide licensee of tosedostat. CTI previously held rights to tosedostat in the Americas under a Licence Agreement with Chroma. Chroma no longer retains any ongoing rights or financial interest in tosedostat.
CTI BioPharma Corp
Breaking News
Subscribe to VCpost newsletter
Most Popular
- Walmart Founder's Son Rob Walton to Step Down From Board
- US Secretary of State Antony Blinken Calls on China to Treat American Companies Fairly During Visit to Shanghai
- Walgreens to Open a New Pharmacy Offering Cell and Gene Therapies to Patients With Chronic Diseases Like Cancer
- How to Apply for Social Security Spousal Benefits; Here's How You May Boost Your Money!
- How to Get IRS Unclaimed Tax Refunds: Here's What to Do If You Think You Have Pending Payments
- Tesla Cybertruck Owners Can Now Power Their Homes Using The Vehicle's Battery; But Installation Price Is Expensive
- Celebrity Designer Nancy Gonzalez Jailed for Smuggling Crocodile, Python Handbags
- More US Voters Trust Donald Trump Than Joe Biden to Deal With Inflation and Cost of Living, New Poll Shows